Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.

Start Date31 Dec 2019

Sponsor / Collaborator-

NCT05993299

/ CompletedPhase 2

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Start Date31 Dec 2019

Sponsor / Collaborator

MDD US Operations LLC

NCT03697824

/ WithdrawnPhase 2

Open-Label Phase 1b/2a Clinical Trial to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells (GSK3377794) in Combination With Anti-Cancer Agents Including Pembrolizumab in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Synovial Sarcoma

Adoptive T-cell therapy is a therapeutic approach that aims to generate an anti-tumor T-cell immune response by infusing a cancer subjects own T-cells obtained by leukapheresis, engineered and expanded in-vitro to express a tumor specific T-cell receptor. NY-ESO-1 and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types, including synovial sarcoma. This is an open-label study to evaluate the safety and efficacy of GSK3377794 (genetically engineered NY-ESO-1 Specific [c259] T Cells), in combination with anticancer agents including pembrolizumab in subjects with NY-ESO-1 and/or LAGE-1a positive relapsed and refractory synovial sarcoma. The study will consist of a target expression screening to determine if subjects are human leukocyte antigen (HLA)-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive and if their tumors express NY-ESO-1 and/or LAGE-1a, followed by a leukapheresis screening phase of up to 42 days prior to leukapheresis. Eligible subjects will enter a leukapheresis phase followed by lymphodepletion phase with cyclophosphamide and fludarabine. During the treatment phase, subjects will be administered GSK3377794 on Day 1 followed by pembrolizumab infusion once every 3 weeks from Day 22 (or Week 7) for up to 2 years. There will be a long-term follow-up phase from the end of treatment phase and for up to 15 years from the date of GSK3377794 administration.

Start Date25 Feb 2019

Sponsor / Collaborator

GSK Plc

[+1]

100 Clinical Results associated with Letetresgene autoleucel

100 Translational Medicine associated with Letetresgene autoleucel

100 Patents (Medical) associated with Letetresgene autoleucel

Literatures (Medical) associated with Letetresgene autoleucel

01 Nov 2025·Translational Lung Cancer Research

Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?

Communications

Author: Barba, Andrés ; Majem, Margarita ; Molina-Pérez, M Alejandra ; Sanz-Beltran, Judit ; Martínez-Recio, Sergio ; Portu, Mikel

01 Sep 2025·Translational Lung Cancer Research

NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel

Communications

Author: Califano, Raffaele ; Gómez-Randulfe, Igor ; Monaca, Federico

20 May 2025·JOURNAL OF CLINICAL ONCOLOGY

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma

Article

Author: Nathenson, Michael J. ; Van Tine, Brian A. ; Zajic, Stefan ; Preston, Jessica ; Tap, William D. ; Goodison, Sophia ; Suchindran, Sunil ; Corigliano, Ellie ; Liebner, David ; Schuetze, Scott M. ; Bhaskar, Aishwarya ; Somaiah, Neeta ; Kim, Jaegil ; Kaczynski, Heather ; Klohe, Erika ; Eleftheriadou, Ioanna ; Kapoor, Gurpreet S. ; D'Souza, Jimson W. ; Druta, Mihaela ; D'Angelo, Sandra P.

PURPOSE:

The cancer/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS).

METHODS:

In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1c 259 T letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01–, HLA-A*02:05–, and/or HLA-A*02:06–positive advanced/metastatic NY-ESO-1–expressing MRCLS. Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR). The primary end point was investigator-assessed overall response rate (ORR). Safety was assessed through adverse event (AE) reports. Correlative biomarker analyses were performed post hoc. The trial is registered at ClinicalTrials.gov (identifier: NCT02992743 ).

RESULTS:

Of 23 enrolled patients, 10 in cohort 1 and 10 in cohort 2 received lete-cel. Investigator-assessed ORR was 20% (95% CI, 2.5 to 55.6) and 40% (95% CI, 12.2 to 73.8), median duration of response was 5.3 months (95% CI, 1.9 to 8.7) and 7.5 months (95% CI, 6.0 to not estimable [NE]), and median progression-free survival was 5.4 months (95% CI, 2.0 to 11.5) and 8.7 months (95% CI, 0.9 to NE) in cohorts 1 and 2, respectively. AEs included cytokine release syndrome and cytopenias, consistent with T-cell therapy/LDR. Post hoc correlative biomarkers showed T-cell expansion and persistence in both cohorts.

CONCLUSION:

To our knowledge, this study is the first demonstrating the clinical promise of lete-cel in HLA-/NY-ESO-1-positive patients with advanced MRCLS.

News (Medical) associated with Letetresgene autoleucel

20 Oct 2025

·www.adaptimmune.com

Adaptimmune Announces Delisting from Nasdaq

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "As we noted previously, the transaction with USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, "US WorldMeds") followed an extensive review of strategic alternatives and represented the best path forward for Adaptimmune, our patients and other stakeholders. Since closing the transaction on July 31, 2025, we have been restructuring to support the assets transferred to US WorldMeds, and have continued our efforts to maximize value from our remaining assets including programs targeting PRAME and CD70. The delisting from Nasdaq and deregistration should facilitate cost reductions and further support our goal to maximize value going forward." As previously reported by the Company, the Company received a written notice on September 22, 2025, from the Nasdaq Hearings Panel (the "Panel") confirming that the Company had been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the "Bid Price Rule"). The Company had until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 would result in the delisting of the Company's ADSs from Nasdaq. On October 16, 2025, the Company notified The Nasdaq Stock Market, LLC, pursuant to authorization by the Board on October 15, 2025, that it intends to file a Form 25 with the U.S. Securities and Exchange Commission (the "SEC") on or about October 28, 2025 to effect the voluntary delisting of the Company's ADSs from Nasdaq and to deregister the ADSs under Section 12(b) of the Exchange Act. Following confirmation by The Nasdaq Stock Market, LLC on October 17, 2025, the Company currently expects that the trading of its ADSs on Nasdaq will be suspended following the closing of trading on Nasdaq on or about October 27, 2025. Following the delisting, any trading in the Company's ADSs would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company currently expects that its ADSs will be quoted on the OTC Pink Limited Market, a market operated by OTC Markets Group Inc. (an "OTC market"), so that a trading market may continue to exist for its ADSs. There is no guarantee, however, that a broker will continue to make a market in the ADSs and that trading of the ADSs will continue on an OTC market or otherwise. Ninety days after the date of filing of the Form 25, the deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is expected to become effective. Following the delisting of the Company's ADSs from Nasdaq, the Company intends to file a Form 15 with the SEC certifying that it has fewer than 300 shareholders of record, upon which the Company's filing obligations under the Exchange Act will immediately be suspended, including the obligations to file all periodic reports. The Board believes that the decision to delist the ADSs from Nasdaq and deregister and suspend the Company's reporting obligations under the Exchange Act is in the best interests of the Company and the holders of its ordinary shares and ADSs. As the Company continues with its efforts to maximize value from its remaining assets, the Board has determined that the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages to the Company and the holders of its ordinary shares and ADSs. The Board's decision was based on careful review of numerous factors, including the potential for eliminating the significant costs associated with preparing and filing periodic reports with the SEC and the legal, audit and other expenses associated with being a public reporting company listed on Nasdaq, as well as the substantial costs and demands on management's time under the Sarbanes-Oxley Act of 2002, SEC rules and Nasdaq listing standards. About Adaptimmune We are a biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. In August 2024, the U.S. Food and Drug Administration ("FDA") approved our first biologics license application ("BLA") for TECELRA® (afamitresgene autoleucel) ("TECELRA"), which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S. In July 2025, TECELRA was acquired by US WorldMeds alongside letetresgene autoleucel ("lete-cel"), for people with synovial sarcoma and myxoid liposarcoma, in relation to which a commercial launch was planned for 2026. A third clinical candidate, uza-cel, and the collaboration with Galapagos related to that cell therapy was also assigned to US Worldmeds as part of the transaction. We are working to ensure a smooth transition of TECELRA, lete-cel and uza-cel to US WorldMeds. We have also developed certain pre-clinical assets including our PRAME directed T-cell therapy and our CD-70 directed TRuC therapy. We are looking for strategic options in relation to these assets. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Exchange Act. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: risks associated with, and the timing and effectiveness of, the Company's voluntary delisting from Nasdaq; the Company's plans with respect to the delisting and deregistration of its ADSs; uncertainties regarding eligibility for and timing of quotation on an OTC market; and the trading of the Company's ADSs following the voluntary delisting of the ADSs from Nasdaq. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Adaptimmune Contact Investor Relations and Media Relations Adrian Rawcliffe, Chief Executive Officer Adrian.Rawcliffe@adaptimmune.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271003 SOURCE Adaptimmune Therapeutics PLC Released October 20, 2025

Cell TherapyAcquisitionImmunotherapy

13 Aug 2025

·www.adaptimmune.com

Adaptimmune Reports Q2 Financial Results and Provides Business Update

Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds for $55 million upfront with up to $30 million in future milestone payments Following the transaction, Adaptimmune has repaid its debt and is restructuring to maximize value from remaining assets, including PRAME and CD70 directed T-cell therapies Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) today reported financial results and provided a business update for the second quarter ended June 30, 2025. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "The launch of TECELRA continued to accelerate through Q2 with an increase of over 150% in patients invoiced and in revenue. The full network of ATCs is close to completion with 30 now accepting referrals. Our manufacturing organization continues to deliver with a 100% commercial manufacturing success rate through to the end of Q2. The transaction with US WorldMeds will ensure that patient access to TECLRA continues and also places lete-cel in capable hands leading up to its planned launch in 2026. As we noted when we announced the transaction on July 28, this deal follows an extensive review of strategic alternatives and represents the best path forward for Adaptimmune, our patients and stakeholders. Since closing the transaction on July 31, we have repaid our debt facility with Hercules Capital and are restructuring to support the assets transferred to US WorldMeds, and to maximize value from our remaining assets including programs targeting PRAME and CD70." Financial Results for the six months ended June 30, 2025 Cash / liquidity position: As of June 30, 2025, Adaptimmune had cash and cash equivalents of $26.1 million and Total Liquidity[1] of $26.1 million, compared to $91.1 million and $151.6 million respectively, as of December 31, 2024. Revenue: Revenue for the three and six months ended June 30, 2025, was $13.7 million and $21.0 million respectively, compared to $128.2 million and$133.9 million for the same periods in 2024. Revenue from development activities decreased by 96% for the six months ended June 30, 2025, compared to the same period in 2024. This decline was primarily due to the termination of the Genentech collaboration in April 2024 which resulted in the recognition of a cumulative catch-up adjustment of $101.3 million for the six months ended June 30, 2024. The product revenue has increased due to product sales commencing following the FDA approval of TECELRA on August 1, 2024. Research and development (R&D) expenses: R&D expenses for the three and six months ended June 30, 2025, were $23.0 million and $51.8 million respectively, compared to $40.4 million and $75.7 million for the same periods in 2024. R&D expenses decreased due to a decrease in the average number of employees engaged in R&D following the restructuring and reprioritization of activities that was announced in November 2024 and a decrease in subcontracted expenditure and manufacturing facilities expenses , offset by a decrease in offsetting reimbursements receivable for R&D tax and expenditure credits. Selling, general and administrative (SG&A) expenses: SG&A expenses for the three months and six months ended June 30, 2025, were $18.5 million and $41.8 million respectively, compared to $19.1 million and $38.8 million for the equivalent periods in 2024. SG&A expenses increased due to restructuring charges for the restructuring program initiated in the fourth quarter of 2024 for which there was no equivalent in the same periods of 2024 which was partially offset by a decrease in share-based compensation expense due to forfeitures arising as a result of this restructuring program. Also, there was an increase in accounting, legal and professional fees due to fees relating to business development work. Net loss: Net loss attributable to holders of the Company's ordinary shareholders for the three months and six months ended June 30, 2025, were $30.3 million and $77.9 million respectively ($(0.02) and $(0.05) per ordinary share), compared to profits of $69.5 million and $21.0 million ($0.05 and $0.01 per ordinary share), for the equivalent periods in 2024. [1] Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below. As a result of the transaction with US WorldMeds and repayment of all sums under the loan agreement with Hercules Capital Inc, we consider that the cash and cash equivalents of the Company will be sufficient to meet our planned operating requirements through the 12 months following the filing of our Quarterly Report for the second quarter of 2025. About Adaptimmune Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Total Liquidity (a non-GAAP financial measure) Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in thousands): The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage. Condensed Consolidated Statement of Operations (unaudited, in thousands, except per share data) Condensed Consolidated Balance Sheets (unaudited, in thousands, except share data) Condensed Consolidated Cash Flow Statement (unaudited, in thousands) Adaptimmune Contact Investor Relations and Media Relations Adrian Rawcliffe, Chief Executive Officer Adrian.Rawcliffe@adaptimmune.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262197 SOURCE Adaptimmune Therapeutics PLC Released August 13, 2025

Financial StatementCell Therapy

04 Aug 2025

·www.prnewswire.com

US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel

LOUISVILLE, Ky., Aug. 4, 2025 /PRNewswire/ -- US WorldMeds (USWM) reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc's (Adaptimmune) cell–therapy assets—including TECELRA® (afamitresgene autoleucel), lete–cel, afami–cel, and uza–cel. The acquisition was first announced on July 28, 2025 and has now been finalized. Under the terms of the Asset Purchase Agreement, USWM paid $55 million in cash at closing and will fund up to an additional $30 million in performance-based milestone payments tied to commercial and regulatory outcomes. Adaptimmune has retained rights to its pre–clinical programs, including PRAME– and CD70–directed T–cell therapies, and its allogeneic pipeline. Key Highlights: Patient care continuity: TECELRA will remain available to patients without interruption, now under USWM's stewardship. Future development: USWM plans to bring lete–cel to the U.S. market, with potential regulatory approval anticipated in 2026, and will continue development of uza–cel in collaboration with Galapagos. Employee transition: Approximately half of Adaptimmune's U.S.-based workforce is being offered roles at USWM to support commercialization, production, and ongoing development of the acquired assets. Transition support: Adaptimmune is providing transition services through June 2026 to ensure operational continuity. Breck Jones, Chief Executive Officer of US WorldMeds, commented: "With the transaction now complete, we are excited to officially welcome Adaptimmune's programs and people into our organization. We are committed to building on the strong foundation Adaptimmune has established and advancing these therapies to bring lasting impact to patients with high unmet needs." TD Cowen acted as financial advisor, and Ropes & Gray LLP provided legal counsel, to Adaptimmune. Gibson, Dunn & Crutcher LLP provided legal counsel to US WorldMeds. The transaction was financed by debt financing led by funds managed by Oaktree Capital Management, L.P. ("Oaktree"), with participation from funds managed by Athyrium Capital Management, LP ("Athyrium"). Indication TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you. TECELRA is approved based on patient response data. Additional data are needed to confirm the clinical benefit of TECELRA. It is not known if TECELRA is safe and effective in children. Important Safety Information Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA. After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 4 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule. Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner. The most common side effects of TECELRA include nausea, vomiting, fatigue, infection, constipation, fever (100.4°F/38°C or higher), abdominal pain, difficulty breathing, decreased appetite, diarrhea, low blood pressure, back pain, fast heart rate, chest pain, general body swelling, low white blood cells, low red blood cells, and low platelets. You are encouraged to report side effects to the FDA at (800) FDA–1088 or . Please see Full Prescribing Information, including Medication Guide, at Tecelra.com. About US WorldMeds US WorldMeds is a U.S.-based pharmaceutical company focused on rare and specialty treatments. Our portfolio includes approved therapies for rare diseases and bleeding disorders, including approved therapies Iwilfin® an Revonto®. With this acquisition, we expand further into oncology and cell therapy, reinforcing our commitment to bringing life-changing therapies to patients. Media Contact: Name: Jessica Tracy Title: VP, Commercial Operations US WorldMeds Ventures, LLC Phone: 1-833-935-6676 Email: [email protected] SOURCE US WorldMeds WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionCell TherapyImmunotherapyDrug Approval

100 Deals associated with Letetresgene autoleucel

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myxoid Liposarcoma	Phase 3	United Kingdom	Adaptimmune Ltd.	-
Synovial Sarcoma	Phase 3	United Kingdom	Adaptimmune Ltd.	-
LAGE-1a Positive Solid Tumors	Phase 2	United States	-	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Canada	-	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	France	-	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Italy	-	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Netherlands	-	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	Spain	-	31 Dec 2019
LAGE-1a Positive Solid Tumors	Phase 2	United Kingdom	-	31 Dec 2019
NY-ESO-1 Positive Solid Tumors	Phase 2	United States	-	31 Dec 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01343043 (ASCO2026)	Phase 2	Synovial Sarcoma	14	lete-cel	gudwctxrui(csrdmuqbsu) = wagbvyeoaf pchitxizgv (vyogwabpnp ) View more	Positive	29 May 2026
				afami-cel	gudwctxrui(csrdmuqbsu) = kfvkoeoice pchitxizgv (vyogwabpnp ) View more
NCT03967223 (IGNYTE-ESO, SITC2025)	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma NY-ESO-1 expression \| HLA-A02:01 \| HLA-A02:05 ... View more	142	Letetresgene autoleucel (synovial sarcoma)	lblcdtytoq(dphxdoqswq) = fvkzxajxke wyeafqomgd (mzgroziwlx ) View more	Positive	05 Nov 2025
				Letetresgene autoleucel (myxoid/round cell liposarcoma)	lblcdtytoq(dphxdoqswq) = dgaqahnzcr wyeafqomgd (mzgroziwlx ) View more
NCT03967223 (IGNYTE-ESO, Company_Website) Manual	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	64	lete-cel	ubosqxfezx(pgfmahtkzz) = dizxtawncu mwnptnrvjh (gnezpihmts ) View more	Positive	13 Nov 2024
				lete-cel (synovial sarcoma)	ubosqxfezx(pgfmahtkzz) = ffmlidefiv mwnptnrvjh (gnezpihmts ) View more
NCT03967223 (IGNYTE-ESO, ASCO2024)	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma NY-ESO-1	98	Lete-cel	wxgdptfqpj(kexaltugpi) = gippbwiooa rvlxzklorr (zdxkcjwpmj, 20.3% - 62.3%) View more	Positive	24 May 2024
NCT03967223 (IGNYTE-ESO , Corporate Publications) Manual	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma Third line	45	lete-cel	lwsihoidzn(acbxowtwut) = ezlimzbdft gtpznnsgcn (pwqehwethx ) View more	Positive	31 Oct 2023
NCT05993299 (CTgov)	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	7	fludarabine+cyclophosphamide+lete-cel	yuhnbwekfd = ujymelylgx bqbtluggzr (edeotyeucr, ppmncenhoa - rgddrbbnxe) View more	-	16 Oct 2023
NCT03168438 (Pubmed \| Blood Adv)	Phase 1	Relapse multiple myeloma	6	Letetresgene autoleucel alone	qwomlrmztf(rqpfbcwlml) = wdkchoblqp xravhyaybv (grdgefjuaw ) View more	-	19 Dec 2022
				Letetresgene autoleucel with pembrolizumab	wdfytqncju(ajmpgljqwx) = upqhwpxgxb yvmijoiqjw (ncvixqwkwc, 11.8 - 88.2) View more
NCT02992743 (MRCLS \| NCT02992743, CTgov)	Phase 2	Myxoid Liposarcoma	23	GSK3377794 (Reduced Lymphodepletion Dose Plus GSK3377794)	tspncqsunb = httfzyowpf bjrbsjqmhv (ripseuxplp, rvvmtrjjrk - khadwohcpb) View more	-	28 Nov 2022
				GSK3377794 (Standard Lymphodepletion Dose Plus GSK3377794)	tspncqsunb = tskeyvzota bjrbsjqmhv (ripseuxplp, mcsastgbet - xztvuvkhtg) View more
NCT02992743 (MRCLS, ASCO2022) Manual	Phase 2	Myxoid Liposarcoma	20	fludarabine+cyclophosphamide+GSK3377794 (Cohort 1 [C1])	tflijeatnj(idfpuslkor) = rxidrqojnx bofgbooctq (dbaapennid ) View more	Positive	02 Jun 2022
				fludarabine+cyclophosphamide+GSK3377794 (Cohort 2 [C2])	tflijeatnj(idfpuslkor) = timqdyommv bofgbooctq (dbaapennid ) View more
NCT03168438 (CTgov)	Phase 1	Relapse multiple myeloma \| Multiple Myeloma	6	fludarabine+cyclophosphamide+GSK3377794 (GSK3377794)	ccejuspwvc = icgngpkdsf qrtpppjlnk (rxtxbxlcct, onpavzrqyb - pksdhchenu) View more	-	11 Jan 2022
				Pembrolizumab+GSK3377794 (GSK3377794+Pembrolizumab)	ccejuspwvc = huzccompbu qrtpppjlnk (rxtxbxlcct, aqhrvqlxnm - felqdlxcfc) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis